MDT-1118 Japan DT Study

Exclusion Criteria

• •1. Patients with INTERMACS profile 1
• •2. Existence of any ongoing mechanical circulatory support (MCS) other than an intra-aortic balloon pump (IABP)
• •3. Prior cardiac transplant
• •4. History of confirmed, untreated abdominal/ thoracic aortic aneurysm \> 5 cm, or cardiac aneurysm or intraventricular septum rupture
• •5. Severe calcification in thoracic aorta
• •6. Cardiothoracic surgery within 14 days of implantation
• •7. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave changes on the ECG, diagnostic biomarkers, ongoing pain and hemodynamic abnormalities as described in the guidelines published in ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction1
• •8. Patients eligible for cardiac transplantation
• •9. On ventilator support for \> 72 hours within the four days immediately prior to implantation
• •10. Pulmonary embolus within 21 days of implantation as documented by computed tomography (CT) scan or magnetic resonance imaging (MRI)
• •11. Symptomatic cerebrovascular disease, stroke within 180 days of implantation or \> 80% stenosis of carotid or cranial vessels
• •12. Patient seems difficult to control device by oneself due to cerebral disorder
• •13. History of drug intoxication or alcohol dependence
• •14. Uncorrected moderate to severe aortic insufficiency. Correction may include repair or bioprosthesis at the time of implant
• •15. Severe right ventricular failure as defined by the anticipated need for right ventricular assist device (RVAD) support or extracorporeal membrane oxygenation (ECMO) at the time of screening or right atrial pressure \> 20 mmHg on multiple inotropes or right ventricular ejection fraction (RVEF) \<15% with clinical signs of severe right heart failure (e.g. Lower extremity edema, ascites or pleural effusions refractory to treatment with diuretics and two inotropic drugs)
• •16. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and laboratory testing, including but not limited to, continued positive cultures, elevated temperature and white blood cell (WBC) count, hypotension, tachycardia, generalized malaise despite appropriate antibiotic, antiviral or antifungal treatment
• •17. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count \< 75,000, INR \> 2.0 or PTT \> 2.5 times control in the absence of anticoagulation therapy)
• •18. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or postoperative therapy that the investigator may administer based upon the patient's health status
• •19. Serum creatinine \> 3.0 mg/dL within 72 hours of implantation or requiring dialysis or ultrafiltration
• •20. Specific liver enzymes \[AST (SGOT) and ALT (SGPT\] \> 3 times upper limit of normal within 72 hours of implantation
• •21. A total bilirubin \> 3 mg/dL within 72 hours of implantation, or biopsy proven liver cirrhosis or portal hypertension
• •22. Patients with a mechanical heart valve
• •23. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease, obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or restrictive cardiomyopathy
• •24. History of severe COPD or severe restrictive lung disease (e.g FEV1 \<50%) or severe pulmonary hypertension
• •25. Participation in any other study involving investigational drugs or devices
• •26. Severe illness, other than heart disease, which would limit survival to \< 3 years
• •27. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities
• •28. Pregnancy
• •29. Patient unwilling or unable to comply with study requirements
• •30. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of the investigator
• •31. Inadequate family/social support
• •32. Systemic disease including collagen disease, insulin dependent severe diabetes or irreversible multi-organ failure.